Physician

Kyle Charles Harner, M.D

According to 2025 Medicare claims, Kyle Harner, M.D (NPI: 1073547931) practices rheumatology in the Greenville, NC market, with the plurality of this provider's patient population coming from Pitt, NC. This provider's primary affiliated billing organization is CAROLINA ARTHRITIS CENTER, PA (NPI: 1477549780; TIN: 56-2257862) and primary practice location at 27834-3776. Harner is affiliated with the Sentara Accountable Care Organization, LLC (ACO ID: A4868), participating under the MSSP model.

Harner's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 341 traditional Medicare patients, billed 84,818 HCPCS/CPT codes, and received $1,220,721 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,636 prescription claims across 398 beneficiaries totaling $1,759,455 in drug costs, led by Enbrel Sureclick (Etanercept). 2018 DME data shows 12 claims. Open Payments data shows 28 records totaling $1,127. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have risen steadily, from $904,078 to $1,759,455. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $7,341 to $268.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	528	32,369	$842,405
2016	536	32,675	$929,082
2017	558	44,821	$1,190,461
2018	577	37,825	$1,225,991
2019	855	154,106	$3,303,803
2020	752	131,962	$2,614,818
2021	504	93,512	$1,888,472
2022	427	77,513	$1,622,282
2023	361	73,732	$1,365,136
2024	341	84,818	$1,220,721

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	381	3,954	$904,078
2016	387	3,952	$1,070,767
2017	393	3,973	$1,014,171
2018	414	4,218	$957,857
2019	450	4,420	$992,757
2020	444	4,417	$1,029,948
2021	465	4,432	$984,268
2022	428	4,159	$1,241,553
2023	384	3,673	$1,622,393
2024	398	3,636	$1,759,455

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	11	$115
2016	N/R	34	$1,059
2017	N/R	11	$131
2018	N/R	12	$86
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	329	656	$84
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	183	279	$11
36415	Insertion of needle into vein for collection of blood sample	173	334	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	136	261	$8
82565	Blood creatinine level	143	266	$5

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Enbrel Sureclick	Etanercept	31	1,204	$399,925
Humira(Cf) Pen	Adalimumab	40	1,120	$388,773
Humira	Adalimumab	13	364	$170,989
Rinvoq	Upadacitinib	19	570	$125,749
Humira(Cf)	Adalimumab	13	364	$88,550

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	28	$1,127	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Kyle Charles Harner, M.D?

Tedicare shows public-source Medicare data for Kyle Charles Harner, M.D (NPI 1073547931), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Kyle Charles Harner, M.D have ACO affiliation data?

Kyle Charles Harner, M.D is shown with ACO affiliation data for Sentara Accountable Care Organization, LLC (MSSP, ACO ID A4868).

What billing organization is linked to Kyle Charles Harner, M.D?

Kyle Charles Harner, M.D is linked to CAROLINA ARTHRITIS CENTER, PA (billing NPI 1477549780) in the available physician profile data.

Does Kyle Charles Harner, M.D have Open Payments data?

Kyle Charles Harner, M.D has 28 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.